Lormetazepam

CLINICAL USE

Benzodiazepine:Insomnia (short-term use)

DOSE IN NORMAL RENAL FUNCTION

0.5–1.5 mg at night

PHARMACOKINETICS

Molecular weight :335.2

%Protein binding :85

%Excreted unchanged in urine : <6 (86 as metabolites)

Volume of distribution (L/kg) :4.6

half-life – normal/ESRD (hrs) :11–16/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function. Start with small doses

<10 : Dose as in normal renal function. Start with small doses

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in GFR <10 mL/min

HD :Not dialysed. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antibacterials: metabolism possibly increased by rifampicin

Antipsychotics: increased sedative effects

Antivirals: concentration possibly increased by ritonavirDisulfiram: metabolism inhibited, increased sedative effectsSodium oxybate: enhanced effect – avoid concomitant use

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Increased CNS sensitivity in renal impairmentLong-term use may lead to dependence and withdrawal symptoms in certain patientsThe half-life of the glucuronide metabolite is increased in renal impairment

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home